VIGL Stock Price, Vigil Neuroscience, Inc. Quote, Chart

Market Summary

USD2.81+0.06

Market Closed

2.18%

VIGL Stock Price

View Fullscreen

VIGL RSI Chart

VIGL Valuation

Market Cap

101.4M

Price/Earnings (Trailing)

-1.23

Price/Free Cashflow

-1.43

VIGL Price/Earnings (Trailing)

VIGL Profitability

Return on Equity

-71.09%

Return on Assets

-58.67%

Free Cashflow Yield

-70.03%

VIGL Fundamentals

VIGL Earnings

Earnings (TTM)

-82.6M

Earnings Growth (Yr)

-20.15%

Earnings Growth (Qtr)

-8.19%

Breaking Down VIGL Revenue

Last 7 days

-15.2%

Last 30 days

-5.4%

Last 90 days

-2.8%

Trailing 12 Months

-72.2%

How does VIGL drawdown profile look like?

VIGL Financial Health

Current Ratio

10.45

VIGL Investor Care

Shares Dilution (1Y)

3.49%

Diluted EPS (TTM)

-2.13

Tracking the Latest Insider Buys and Sells of Vigil Neuroscience, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 20, 2023	magovcevic-liebisch ivana	bought	15,000	3.75	4,000	president and ceo
Nov 18, 2022	papapetropoulos spyros	acquired	567	1.89	300	chief medical officer
Nov 18, 2022	papapetropoulos spyros	sold	-4,200	14.00	-300	chief medical officer
May 17, 2022	thorp clay	bought	44,189	2.9671	14,893	-
May 16, 2022	thorp clay	bought	60,221	2.7622	21,802	-
May 05, 2022	thackaberry evan	bought	6,000	4.00	1,500	svp, head of early development
May 03, 2022	magovcevic-liebisch ivana	bought	3,940	3.9402	1,000	president and ceo
May 03, 2022	verni christopher	bought	15,074	3.7686	4,000	general counsel
May 03, 2022	papapetropoulos spyros	bought	13,591	3.3978	4,000	chief medical officer
May 03, 2022	ziolkowski jennifer lynn	bought	15,097	3.7744	4,000	chief financial officer

Which funds bought or sold VIGL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.66	-1,578,190	2,701,290	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	16.41	-212,753	575,276	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	-16,226	26,996	-%
Feb 15, 2024	BARCLAYS PLC	added	18.36	-145,000	419,000	-%
Feb 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	new	-	1,808,710	1,808,710	0.29%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	34,402	34,402	-%
Feb 15, 2024	Legal & General Group Plc	unchanged	-	-3,240	5,268	-%
Feb 14, 2024	ArrowMark Colorado Holdings LLC	new	-	978,375	978,375	0.01%
Feb 14, 2024	ORBIMED ADVISORS LLC	unchanged	-	-902,270	1,517,250	0.03%

Are Funds Buying or Selling VIGL?

Are funds buying VIGL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VIGL

No. of Funds

Unveiling Vigil Neuroscience, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 29, 2024	artal international s.c.a.	4.9%	1,811,191	SC 13G/A
Feb 14, 2024	citadel advisors llc	6.0%	6	SC 13G/A
Feb 14, 2024	deep track capital, lp	9.62%	3,649,726	SC 13G/A
Feb 12, 2024	flynn james e	3.27%	1,173,523	SC 13G/A
Feb 09, 2024	artal international s.c.a.	5.0%	1,811,191	SC 13G/A
Feb 14, 2023	citadel advisors llc	6.1%	6	SC 13G/A
Feb 14, 2023	hatteras venture partners vi, lp	4.4%	1,562,578	SC 13G
Feb 13, 2023	artal international s.c.a.	6.3%	2,243,352	SC 13G/A
Feb 10, 2023	flynn james e	5.77%	2,052,010	SC 13G/A
Feb 10, 2023	vida ventures gp iii, l.l.c.	14.1%	5,015,929	SC 13D

Recent SEC filings of Vigil Neuroscience, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	PRE 14A	PRE 14A
Mar 29, 2024	SC 13G/A	Major Ownership Report
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	S-8	Employee Benefits Plan
Mar 20, 2024	3	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Vigil Neuroscience, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-2.93%	-28.56%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-2.14%	-28.32%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	5.64%	-9.07%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-9.46%	-28.45%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.01	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.44	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-21.26%	-56.58%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-14.69%	262.26%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	-4.49%	-3.41%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	67.92%	36.92%	-0.23	2.14	-13.45%	66.37%

Vigil Neuroscience, Inc. News

Latest updates

Vigil Neuroscience, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet									(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-11.5%	141	159	175	192	200	216	158	173	102
Current Assets	-12.8%	122	140	156	172	198	213	156	170	97.00
Cash Equivalents	-8.5%	52.00	57.00	59.00	96.00	187	204	149	163	92.00
Net PPE	-5.1%	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00
Liabilities	5.5%	25.00	23.00	22.00	21.00	11.00	10.00	7.00	7.00	10.00
Current Liabilities	15.0%	12.00	10.00	8.00	7.00	11.00	10.00	7.00	7.00	10.00
Shareholder's Equity	-14.4%	116	136	154	171	189	206	151	166	-69.44
Retained Earnings	-11.1%	-222	-200	-180	-159	-140	-121	-104	-87.20	-71.83
Additional Paid-In Capital	0.8%	339	336	334	331	329	328	255	253	2.00
Shares Outstanding	0.0%	36.00	36.00	36.00	36.00	36.00	29.00	28.00	28.00	2.00
Float	-	-	-	233	-	-	-	30.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	10.4%	-15,510	-17,314	-15,353	-22,186	-17,087	-15,925	-13,993	-18,144	-17,347	-11,073	-6,164	-4,763
Share Based Compensation	2.5%	2,486	2,426	2,257	1,734	1,501	1,494	1,461	1,021	762	556	434	333
Cashflow From Investing	-30.4%	10,655	15,314	-22,103	-69,004	-272	-416	-91.00	-142	-	-	-	-
Cashflow From Financing	0%	53.00	53.00	579	203	101	71,292	-328	90,190	-1,862	89,704	-	-

VIGL Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Operating expenses:

Research and development

^[1]

$ 60,934

$ 47,444

General and administrative

27,932

21,440

Total operating expenses

88,866

68,884

Loss from operations

(88,866)

(68,884)

Other income (expense):

Interest income, net

6,241

623

Other income (expense), net

(13)

(44)

Total other income (expense), net

6,228

579

Net loss and comprehensive loss

$ (82,638)

$ (68,305)

Net loss per share attributable to common stockholders, basic

$ (2.13)

$ (2.16)

Net loss per share attributable to common stockholders, diluted

$ (2.13)

$ (2.16)

Weighted-average common shares outstanding, basic

38,712,207

31,685,125

Weighted-average common shares outstanding, diluted

38,712,207

31,685,125

Comprehensive loss:

Net loss

$ (82,638)

$ (68,305)

Unrealized gain (loss) on available for sale securities

(5)

Total comprehensive loss

$ (82,643)

$ (68,305)

[1]	Includes related party amounts of $50 for the year ended December 31, 2023, and $295 for the year ended December 31, 2022 (see Note 13).

VIGL Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 51,992

$ 186,605

Marketable securities

65,948

Prepaid expenses and other current assets

3,967

11,200

Total current assets

121,907

197,805

Property and equipment, net

1,745

1,184

Operating lease right-of-use assets

16,147

141

Financing lease right-of-use assets

49

70

Restricted cash

927

Other assets

83

266

Total assets

140,858

200,393

Current liabilities:

Accounts payable

1,946

1,942

Accrued expenses and other current liabilities

^[1]

8,810

9,194

Operating lease liabilities

905

153

Financing lease liabilities

23

Total current liabilities

11,661

11,312

Operating lease liabilities, net of current portion

12,945

Total liabilities

24,606

11,312

Commitments and contingencies (Note 14)

Stockholders' equity

Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 0 share issued and outstanding at December 31, 2023 and December 31, 2022

Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2023 and December 31, 2022; 35,929,035 shares issued as of December 31, 2023 and 35,664,658 shares issued as of December 31, 2022; and 35,884,712 shares outstanding as of December 31, 2023 and 35,620,335 shares outstanding as of December 31, 2022

4

Additional paid-in capital

339,025

329,211

Accumulated other comprehensive loss

(5)

Accumulated deficit

(222,772)

(140,134)

Total stockholders' equity

116,252

189,081

Total liabilities and stockholders' equity

$ 140,858

$ 200,393

[1]	Includes related party amounts of $0 (accrued expenses and other current liabilities) at December 31, 2023; $78 (accrued expenses and other current liabilities) at December 31, 2022 (see Note 13).

About Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
WEBSITE	vigilneuro.com
INDUSTRY	Biotechnology
EMPLOYEES	61

Vigil Neuroscience, Inc. Frequently Asked Questions

What is the ticker symbol for Vigil Neuroscience, Inc.? What does VIGL stand for in stocks?

VIGL is the stock ticker symbol of Vigil Neuroscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vigil Neuroscience, Inc. (VIGL)?

As of Thu Apr 18 2024, market cap of Vigil Neuroscience, Inc. is 101.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIGL stock?

You can check VIGL's fair value in chart for subscribers.

What is the fair value of VIGL stock?

You can check VIGL's fair value in chart for subscribers. The fair value of Vigil Neuroscience, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vigil Neuroscience, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VIGL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vigil Neuroscience, Inc. a good stock to buy?

The fair value guage provides a quick view whether VIGL is over valued or under valued. Whether Vigil Neuroscience, Inc. is cheap or expensive depends on the assumptions which impact Vigil Neuroscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIGL.